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Background: The aim of the study was to evaluate potential chemotherapy-induced microsatellite instability, loss
of heterozygosity, loss of expression in mismatch repair proteins and associations with clinical findings in breast
cancer patients, especially resistance to chemotherapy and/or development of other tumors in the four years
following chemotherapy treatment.
Methods: A comprehensive study of chemotherapy-related effects with a follow-up period of 48 months post
treatment was conducted. A total of 369 peripheral blood samples were collected from 123 de novo breast cancer
patients. Microsatellite instability and loss of heterozygosity in five commonly used marker loci (including Tp53-Alu
of the tumor suppressor gene TP53) were analyzed in blood samples. Sampling was conducted on three occasions;
4–5 weeks prior to the first chemotherapy session (pre-treatment), to serve as a baseline, followed by two
consecutive draws at 12 weeks intervals from the first collection. Mismatch repair protein expression was evaluated
in cancer tissues using immunohistochemistry for three mismatch-repair related proteins.
Results: A total of 70.7% of the patients showed microsatellite instability for at least one locus, including 18.6%
marked as high-positive and 52.1% as low-positive; 35.8% showed loss of heterozygosity in addition to
microsatellite instability, while 29.3% exhibited microsatellite stability. The following incidence rates for microsatellite
instability and loss of heterozygosity were detected: 39.1% positive for Tp53-Alu, 31.1% for locus Mfd41, and 25.3%
for locus Mfd28. A higher occurrence of loss of heterozygosity was noted with alleles 399 and 404 of Tp53-Alu. The
mismatch repair protein expression analysis showed that the chemotherapy caused a loss of 29.3% in hMLH1
expression, and 18.7% and 25.2% loss in hMSH2 and P53 expression, respectively. A strong correlation between low
or deficient hMSH2 protein expression and occurrence of mismatch repair/loss of heterozygosity events in Mfd41,
Tp53-Alu, and Mfd28 was evident. A significant association between mismatch repair/loss of heterozygosity and
incidence of secondary tumors was also established.
Conclusion: Our results suggest that microsatellite instability, loss of heterozygosity, and deficiency in mismatch
repair may serve as early prognostic factors for potential chemotherapy-related side effects in breast cancer
patients.
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The rates of chemotherapy-related secondary cancers have
increased considerably during the last two decades [1-8].
A variety of chemotherapy agents and combinations are
used in oncology clinics, and side effects are inescapable.
Genotoxic side effects in particular are believed to play a
crucial and determinant role in treatment outcome for
some patients [9,10]. Assessing changes at the genetic
level in patients receiving chemotherapy is possible using
several markers, and one of the most reliable choices is
microsatellite markers [11,12].
Microsatellites or simple sequence repeats are tandem
repetitive DNA consisting of arrays of one to five base
pairs with a different number of repeat units. These
DNA sequences are particularly prone to mutations via
insertion–deletion loop formation during DNA synthesis,
generating new allele lengths [13,14]. This microsatellite
instability (MSI) and loss of heterozygosity (LOH) are
the two aberrations known to be early steps in the
tumorigenesis pathway [15,16]. Furthermore, MSI has
been described as a replication error phenotype. Mismatch
repair (MMR) pathways normally correct most of these
replication errors, and microsatellite mutation rates are
significantly elevated in the absence of MMR proteins,
such as hMLH1, hMSH2, hMSH6, and hPMS2 [17-20].
Because systemic chemotherapy is an integral part of
the treatment regimen in breast cancer, a large number
of patients in both adjuvant and palliative settings
show varied adverse effects that include phenotypic
and/or genotoxic features, such as MSI and LOH
[2,21-24]. Changes in the genomes of patients receiv-
ing chemotherapy, especially alkylating agents, can lead
to many abnormal clinical phenotypes, such as a
higher resistance to chemotherapy remedies and sec-
ondary cancers like acute myeloid leukemia and/or
myelodysplasia, with an incidence rate of 1–5% [2,3].
MSI and/or LOH pathways work by accumulating
mutations in genes responsible for tumorigenesis that
are targets for mismatch-induced frameshift mutations
e.g., transforming growth factor β1 receptor type II
[25], insulin-like growth factor type II receptor [26],
and the BAX gene [27]. In 1997, a National Cancer
Institute (NCI) workshop developed the Bethesda
guidelines, a set of clinical criteria to prompt MSI test-
ing [28]. The conference recommended the use of a
panel of five microsatellite sequences to assess instabil-
ity. This panel consisted of two mononucleotide (Bat-
25 and Bat-26) and three dinucleotide (D2S123,
D5S346, and D17S250) repeat sequences. It was unani-
mously agreed that testing should compare DNA from
tumor tissue and normal tissue, and classification of
the results depends on the number of altered micro-
satellite sequences in the tumor relative to the normal
tissue. If alteration is present in two or more of thefive microsatellite sequences, the cancer is classified as
high (MSI-H); if only one is mutated, it is classified as
low (MSI-L); and if no changes are present among the
five microsatellites, the tumor is considered microsatel-
lite stable (MSS) [29]. The NCI panel of markers had
been used frequently as a guideline for survival and
molecular profiling in colorectal cancer and for screen-
ing patients for hereditary nonpolyposis colorectal car-
cinoma (HNPCC) [30,31]. Recently, high MSI detection
was found to have clinical application in assisting the
diagnosis of suspected HNPCC [32]. Many modifica-
tions of this panel have been adopted successfully in
several studies. For instance, Bacher et al. [33] used a
panel of five mononucleotide microsatellites (BAT-25,
BAT-26, NR-21, NR-24 and MONO-27) and found it to
be more sensitive and specific than the original NCI
panel for screening colorectal cancer patients, while
Fonseca et al. 2005 developed and used a set of mar-
kers (that includes BAT-26, BAT-40, MFD-28, MFD-41,
TP53.PCR15.1, TP53ALU) specifically for screening
breast cancer patients [30,33-35].
The five microsatellites (BAT-26, BAT-40, MFD-28,
MFD-41, and TP53ALU) applied in the present study
were also used by Fonseca and co-workers, although
we analyzed a significantly larger and unique cohort
compared to earlier studies [34,36]. Furthermore, the
results presented are from a region with a high inci-
dence of breast cancer, but at the same time for
which epidemiological data are scanty [37,38]. In
addition, an extended follow-up period of 48 months
was included to see whether it was possible to match
the detected MSI, LOH, and MMR expression to clin-
ical findings, especially resistance to chemotherapy
and/or development of other tumors in the four years
following chemotherapy treatment. Collectively, such
data could serve the purpose of establishing a solid
link between chemotherapy and some of its negative
consequences.
Methods
Study design and chemotherapy protocol
The 123 de novo breast cancer patients (ages 26–
79 years) selected for this study had not received any
previous chemotherapy. The chemotherapy regimen was
as follows: 80.5% of the patients received 3–4 cycles of
an FEC regimen, which consists of 5-fluorouracil, epiru-
bicin, and cyclophosphamide (Cytoxan), and was admi-
nistered at a low or high concentration (Table 1). In 46
patients, this regimen was followed by docetaxel. Our re-
search conformed with the Helsinki declaration and
local legislations and has been approved by Al Ain med-
ical district human research ethics committee/ Faculty of
Medicine and Health sciences, University of UAE under
ethical permit No. AAMD/HREC 08/15.
Table 1 Chemotherapy regimen and positive cases detected
Chemotherapy regimen No. of patients No. of MSI-H No. of MSI-L- Recurrence /2nd CA
High conc. FECa










13 0 6 0Adriamycin (Doxorubicin) 60 mg/m2
Cyclophosphamide 600 mg/m2
TCc
3 0 2 0Taxotere (Docetaxel) 75 mg/m2
Cyclophosphamide 600 mg/m2
PTd
2 0 1 0Carboplatin (Paraplatin) AUC 6 mg/ml/min
Taxotere 175 mg/m2
TAe
1 0 0 0Taxotere 90 mg/m2
Avastin (Bevacizumab) 10 mg/kg
THf
3 0 0 0Taxotere 90 mg/m2
Herceptin (Trastuzumab) 4 mg/kg
LTg
1 0 0 0Lapatinib (Tykerb) 1500 mg po
Taxotere 175 mg/m2
TEh
1 0 0 0Epirubicin 75 mg/m2
Taxotere 200 mg/m2
Total 123 23 64 16
Abbreviations: a = 5-Floururacil, Epirubicin and Cyclophosphomide, b = Adriamycin and Cyclophosphamide, c = Taxotere and Cyclophosphamide, d = Paraplatin and
Taxotere, e = Taxotere and Avastin, f = Taxotere and Herceptin, g = Lapatinib and Taxotere, h = Epirubicin and Taxotere.
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A total of 369 peripheral blood samples were collected
from the patients. Sampling was conducted on three
occasions starting from 4–5 weeks prior to the first
chemotherapy session (pre-treatment), to serve as a
baseline, and followed by two consecutive draws at
12-weeks intervals from the first collection. Twelve
weeks interval represents the period required to
complete a standard 3–4 cycles FEC regimen. The first
post-treatment samples would demonstrate the presence
of treatment-related MSI and LOH, and the second
post-treatment samples would show the level of persist-
ence of the first post-treatment findings. Simultaneously,
180 control samples were collected from 60 healthy indi-
viduals without any relevant reported symptoms, follow-
ing the same sampling protocols.In addition to blood sampling, 218 cancer tissues
resected from the study patients were collected from the
pathology department for MMR expression analyses.
Among the collected breast cancer tissues, 54% were
evaluated to be grade III, 30% grade II, 11% grade I,
and 5% grade VI. Follow-up studies were performed for
36–48 months post-chemotherapy treatment. Patients
were monitored for chemotherapy-related MSI and
LOH, MMR expression and tumor recurrences and/or
development of secondary tumors.DNA extraction and LOH and MSI analysis
Genomic DNA was extracted from whole blood using
DNA isolation kit I, on a MagnaPure-LC extraction sys-
tem (Roche, Germany).
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amplify the five loci Mfd41 and Tp53-Alu on chromo-
some 17 and Bat-26, Bat-40, and Mfd28 on chromo-
somes 1, 2, and 10, respectively, using fluorescently
labeled primers; the sequences have been described pre-
viously [39] and these markers were used by Fonseca
et al. [34], for screening breast cancer patients. The PCR
amplifications were performed according to Dietmaier
and co-workers [39] with a slight modification of the
cycling conditions. The specific primer information is
given in Table 2. Amplification reactions were prepared
in 10 μl reaction volumes of 1× Gold AmpliTaq Master
Mix (Applied Biosystems, USA), with the addition of
80 ng purified genomic DNA and adjustment of the final
concentration of primers to 0.4 μM. The following cyc-
ling conditions were applied: initial denaturation at 95°C
for 5 minutes, followed by 31 cycles at 94°C for 1 minute,
55°C for 45 seconds, and 72°C for 50 seconds, with a
final 40-minutes extension at 70°C. All runs included the
use of an internal molecular weight control (LIZ 500
Genescan, Applied Biosystems). PCR products were
loaded on an ABI 3130 genetic analyzer (Applied Biosys-
tems, USA), and fragments were measured and com-
pared using GeneMapper software Version 4.
GeneScan data counted a minimum peak detection
limit of 50 relative fluorescent units using the local
Southern size calling method. Alterations in the number
of microsatellite alleles or allele distribution in the post-
treatment samples compared to the pre-treatment sam-
ples were considered indicators of MSI [34,36,39]. In
addition, when a peak height of one of the two heterozy-
gote alleles was reduced by at least 35%, it was recorded
as LOH [36]. The GeneMapper software is designed to
calculate the LOH in two steps, first by calculating allele
ratio for each sample by dividing the peak height of al-
lele 1 by the peak height of allele 2 of the same sample,
and second by calculating allelic imbalance by dividing
the allele ratio of the pre-treatment sample by the allele
ratio of the first post-treatment sample.Table 2 Characteristics of microsatellite markers analyzed
Name (locus) Primer sequence (5’ to 3’)
TP53-Alu
F. . .GCA CTT TCC TCA ACT CTA CA
R. . .AAC AGC TCC TTT AAT GGC AG
Mfd41 (D17S261)
F. . .CAG GTT CTG TCA TAG GAC TA
R. . .TTC TGG AAA CCT ACT CCT GA
Mfd28 (D10S89)
F. . .AAC ACT AGT GAC ATT ATT TTC
R. . .AGC TAG GCC TGA AGG CTT CT
Bat-40
F. . .ATT AAC TTC CTA CAC CAC AAC
R. . .GTA GAG CAA GAC CAC CTT G
Bat-26
F. . .TGA CTA CTT TTG ACT TCA GCC
R. . .AAC CAT TCA ACA TTT TTA ACC CMMR analysis
Cancer tissues sampled for initial pathological assess-
ment have been used as pre-treatment specimens, while
the surgically resected cancer tissues after chemotherapy
regimen were utilized for post-treatment analysis. Tis-
sues were embedded in paraffin blocks for MMR protein
expression analyses. Healthy tissue from each patient
was used as an internal control in addition to the
standard controls provided by the manufacturer. In the
staining procedure, the TP-125 HLX UltraVision Plus
Anti-Polyvalent HRP detection system (Lab Vision,
USA) was applied, using specific monoclonal antibodies
for hMLH1, hMSH2, and P53 (Sigma Aldrich, Ger-
many). Results were marked as positive when a 10% or
higher proportion of cell nuclei stained positively.
Statistical analyses
Confidence intervals were calculated at the 95% and 99%
levels. Fisher’s exact test and Chi square were used for
statistical analysis, with the SPSS statistical analysis
package. In addition, an inter-rater reliability test using
Cohen's kappa coefficient was used to measure correl-
ation between the MSI and LOH results for the five
markers and low MMR protein expression [40].
Results
Blood samples
Screening of the five microsatellite markers showed that
87 (70.7%) patients out of the total cohort of 123 breast
cancer patients tested positive for at least one locus.
These patients could be classified either as MSI-H due
to MSI/LOH in two or more loci in each individual or
as MSI-L (MSI/LOH in only one locus); 18.6% and
52.1% of patients were categorized in the first and sec-
ond groups, respectively (Table 1). Among the positive
cases, 50% exhibited LOH. The rest of the studied
patients, 36 individuals (29.3%), tested negative for all
markers and were reported as MSS. In terms of the 369
blood samples drawn for the study, we found that 28.5%Unit of repeats PCR-Tmc Dye Size (bp)
5 55°C FAM 382-417
2 55°C NED 153-172
2 55°C FAM 139-156
1 55°C VIC 116-132
1 55°C FAM 112-127
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second post-treatment), and 23.8% samples showed
LOH (11.9% in each post-treatment group).
Comparing the induced changes in the individual
microsatellites of the 87 patients, the following incidence
rates of MSI and LOH were detected. The highest and
lowest incidences were seen with Tp53-Alu (39.1%) and
Bat-26 (4.6%), respectively, while Mfd41 and Mfd28
exhibited intermediate frequencies (Table 3). MSI was
manifested in more than one way; either as additional
peaks or as a novel allele within the size range of the
marker, while a complete or partial loss of one of the
two heterozygote alleles (35–100% loss of the original
peak height) was recorded as an LOH event (Figure 1).
The highest incidence of LOH was recorded in alleles
399 and 404 of microsatellite Tp53-Alu (Figure 1), which
is located within the tumor suppressor gene TP53. In-
deed, Tp53-Alu was the most informative among the five
markers used in this study. Nevertheless, Mfd41 results
approached the same level of instability despite the fact
that it has fewer alleles (Table 3). In addition, Mfd41
showed MSI of alleles 157 and partial LOH of alleles
158 and 159 (Figure 1). No instability was detected in
the microsatellite sequence Bat-40.
Cancer tissues
The results from the immunohistochemistry analysis of
MMR proteins showed that there was a significant differ-
ence (Fisher’s exact test) in MMR protein expression be-
tween cancer tissues sampled prior to chemotherapy and
the resected tissues analyzed after the chemotherapy treat-
ment. The treatment-dependent loss of protein expression
was 29.3% (p< 0.0001) for hMLH1, and the corresponding
loss for P53 and hMSH2 was 25.2% (p< 0.0001) and 18.7%
(p= 0.003), respectively (Figure 2).
An average follow-up of 48 months showed that 13%
of patients had a recurrent primary tumor and/or devel-
oped secondary tumors. All 16 of these patients wereTable 3 Incidence rate of MSI and LOH, number of alleles isol






L= lower allelic imbalance range.
U= upper allelic imbalance range.among those previously detected to have chemotherapy-
related MSI/LOH in their first post-treatment sample,
(11 patients [8.9%] MSI-H and 5 [4.1%] MSI-L). Recur-
rence of the primary disease was noticed in 8 patients,
while secondary tumors were identified in 13 patients
in lungs, brain, liver, bone marrow or blood. Fisher’s
exact test results indicated a significant association
between MSI/LOH and the incidence of secondary
tumors (2-sided Fisher's exact = 0.014, and 1-sided Fisher's
exact = 0.010).
Association of changes with chemotherapy regimen
As Table 1 shows, patients who received the high-
concentration FEC regimen were the majority among
the recruited cohort (68 out of 123 patients); this group
also represented the higher incidence of MSI-H (19 out
of the 23 cases). After 48 months of follow-up, 14 of 16
patients experiencing recurrence were from this group.
The group of patients who received the FEC regimen of
lower concentrations had a higher incidence of MSI-L
and less MSI-H and much less incidence of recurrence
(Table 1). Some smaller groups who received different
regimens had some MSI incidence but were insufficient
in number of positive cases for statistical analysis.
Other statistical analysis
As Table 4 shows, there was a significant (99% significance
level) and strong correlation between low or deficient
hMSH2 protein expression and the occurrence of MSI/
LOH events in Mfd41, Tp53-Alu, and Mfd28. A strong
correlation also emerged between LOH events in Tp53-
Alu and low or deficient P53 expression (kappa= 0.595,
P < 0.0001). No correlation was found between MSI/LOH
events in Bat-26 and Bat-40 and low MMR expression.
Discussion
Our findings clearly demonstrate a significant incidence
of MSI and LOH in three out of the five markersated, and allelic imbalance noticed for each marker
ce of MSI / LOH No. of alleles isolated Allelic imbalance
39.08% 11
L 0.00 - 0.64
U 1.52 - 2.61
31.03% 8
L 0.00 - 0.56
U 1.37 - 2.82
25.28% 5
L 0.00 -0 .61
U 1.42 - 5.83
4.59% 3
L 0.30 - 0.52
U 1.42 - 1.54
0% 4
L 0.73 - 0.79
U 0.94 - 1.22
Figure 1 Microsatellite instability and loss of heterozygosity in TP53-Alu (patient # 41 &103) and Mfd41 (patient # 72 & 56). Upper
panels represent normal genotypes, while the lower panels show examples of MSI and typical LOHs.
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events and low expression of MMR proteins. As noted,
both LOH and MSI are integral parts of the tumorigen-
esis process [15,16]. The incidences of chemotherapy-
related MSI and LOH in post-treatment specimens,
together with the follow-up findings that all cases of
recurrent primary tumors and/or secondary tumors were
encountered in patients diagnosed with MSI/LOH, led
to an initial assumption that MSI and LOH play a piv-
otal role in determining treatment outcome and/or fa-
cilitate the development of secondary tumors. MSI, asFigure 2 Immunohistochemistry reactions for hMSH2, hMLH1 and P5
negative tissues).mentioned above, is a replication error phenotype
resulting from the reduced fidelity of the replication
process [41]. Improperly functioning MMR machinery
has been frequently implicated in the decreased fidelity
or reduced proofreading efficiency in the replication ap-
paratus as related to MSI [42,43]. Low fidelity of DNA
replication, which results in accumulation of mutations,
eventually generates the characteristic genetic instability
phenotypes in precancerous and cancerous cells [44,45].
Research in this field was motivated in the first place by
the findings that HNPCC is manifested with an elevated3 (Upper panel represent positive tissues and lower panel shows
Table 4 Correlation between MMR expression and MSI and LOH events
Mfd41 TP53-Alu Mfd28 Bat-26
hMLH1
Kappa −0.154 0.148 −0.241 −0.062
p-value 0.080 0.101 0.005 0.191
Significance level ns ns ** ns
hMSH2
Kappa 0.822 0.744 0.375 −0.059
p-value < 0.0001 < 0.0001 < 0.0001 0.329
Significance Level *** *** *** ns
P53
Kappa 0.112 0.595 −0.121 0.000
p-value 0.213 < 0.0001 0.168 0.992
Significance Level ns *** ns ns
* kappa =measure of agreement between two tests.
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HNPCC patients have a high incidence of MSI, usually
due to (a) silenced MMR gene(s), as in the case of
hypermethylation of the hMLH1promoter [48]. It
should be kept in mind that replication errors occur in
repetitive DNA sequences at a higher frequency than in
non-repetitive DNA sequences, making these repetitive
sequences more error-prone in nature, and therefore
particularly dependent on an efficient MMR [18,19].
The sequential accumulation of mismatched base pairs
and/or LOH from multiple mutations may lead to de-
regulation of tumor suppressor genes such as TP53,
VHL, FHIT, and Rb, which often are found to be inacti-
vated in early precancerous and cancerous cells [49-51].
Our results showed that the occurrence of MSI and
LOH was highest in the Tp53-Alu microsatellite among
the markers screened, and it was also found to correlate
with low or deficient expression of the hMSH2 and P53
proteins in the de novo breast cancer patients after
chemotherapy. The patients included in this work are a
population that has not been studied previously, to our
knowledge. The detected incidences of MSI, LOH, and
MMR are significant and may play a role in the develop-
ment of secondary malignancies and/or more resistant
phenotypes of cancer.
As an example, the higher incidence of MSI/LOH in
alleles of Tp53-Alu (chromosome 17) may specifically
induce the initiation of these consequences, which might
be reasonable for the multi-task protein TP53, which
plays a role in activating MMR in response to DNA
damage [52]. LOH on chromosome 17 in the vicinity of
the TP53 gene inactivates it as a tumor suppressor in
many tumors [53], which may result in genetic instabil-
ity, a characteristic phenomenon in malignant cells. In
addition, the essential role played byTP53 in initiating
programmed cell death (apoptosis) in response to irrep-
arable damage is disrupted in many cancer cells through
LOH [54-56]. An example of somatic mutations in
tumor suppressor genes associated with a resistantcancer phenotype has been revealed in a recent study in
which somatic mutation in the retinoblastoma gene was
linked with resistance to anthracyclines/mitomycin in
breast cancer patients [57].
Moreover, the MSI/LOH events in alleles of Mfd41
and Mfd28, which correlated with low expression of
hMSH2 and hMLH1, respectively, may be an indication
of a weakened efficiency of the MMR machinery in
patients. The strong correlation indicates that the MSI/
LOH incidence rate is related directly to the level of ex-
pression of MMR proteins. Similarly, MSI/LOH events
in Mfd41 were correlated with low or deficient hMSH2
expression but not with P53 or hMLH1.These findings
agree with the results from the study by [34] that low
expression of hMSH2 correlated with MSI/LOH in
Mfd41. In addition, we identified a similar correlation
between low expression of hMSH2 and MSI/LOH in
Tp53-Alu and Mfd28. On the other hand, our outcomes
are not in concordance with their results of no correl-
ation between hMLH1 or P53 expression and MSI/LOH
events. We found a significant correlation between low
expression of hMLH1 and P53 with MSI/LOH events in
Mfd28 and Tp53-Alu, respectively.
In terms of the influence of dosing regimen, patients
on the high-concentration FEC regimen--most of the
cohort--had a greater number of MSI-H outcomes and
were by far the most represented among the recur-
rences. The patients receiving the lower-concentration
regimen had a much higher rate of MSI-L outcomes and
far fewer cases of recurrence. These results provide in-
direct evidence of dose effect in chemotherapy-related
side effects. However, some limitations and difficulties
should be mentioned; for instance, we needed to repeat
PCR runs and to do fine tuning for reaction conditions
and fragment analysis in 32% of the patients to reduce
stuttering and yield more clear results. Moreover, in
twelve cases where patients have to move or discontinue
their treatment in Tawam hospital, they were replaced
by new participants and in five patients when the first
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reported to the pathology department in Tawam hospital
the samples could not be successfully retrieved.
In conclusion, MSI/LOH events play a role in tumori-
genesis as two of the genetic instability features in precan-
cerous cells. Screening of breast cancer patients receiving
chemotherapy for MSI and LOH can be of predictive
value in assessing the level of chemotherapy-induced gen-
etic instability and the possible development of secondary
malignancies and/or resistant cancer phenotypes.
Conclusions
Chemotherapy-induced genotoxic side effects especially
MSI and LOH were detected in de novo breast cancer
patients after 12 weeks of receiving their first treatment.
During the four years follow-up period low MMR expres-
sion was noted, and correlated with clinical phenotypes
such as secondary tumors or higher chemotherapy-
resistant cancers. Of special interest was the higher inci-
dence of LOH in two of the alleles of TP53-Alu, the
microsatellite located within the tumor suppressor gene
TP53. MSI/LOH of this microsatellite was strongly corre-
lated with low or deficient MMR protein expression. A
significant association between MSI/LOH and incidence
of secondary tumors was also established in the study.
Our results suggest that MSI, LOH, and MMR may serve
as early prognostic factors for potential chemotherapy-
related side effects in breast cancer patients.
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